Portfolio company Syntis Bio dosed its first patient in the Phase 1/1b clinical trial of SYNT-101 for obesity.
Syntis Bio is a clinical-stage biopharmaceutical company focused on developing transformative oral therapies that harness the small intestine's unique biology to address global healthcare challenges, including obesity, diabetes, and rare genetic disorders
Syntis Bio is a clinical-stage biopharmaceutical company focused on developing transformative oral therapies that harness the small intestine's unique biology to address global healthcare challenges, including obesity, diabetes, and rare genetic disorders.